Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: The First Twenty Clear all
Completed Phase 1 Interventional

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

NCT01439152
View directory record Official record
Conditions
Oncology
Interventions
BAY94-9343, BAY94-9343 (Expansion), BAY94-9343 (1.8 mg/kg), BAY94-9343 (2.2 mg/kg)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
New Haven, Connecticut • Chicago, Illinois • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Nov 14, 2026, 1:26 AM EST
Completed Not applicable Interventional

Evaluating the Efficacy of Pathways Parent-Mediated Early Autism Intervention on Social Attention and Language

NCT05604326
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pathways Intervention, Parent Education Intervention (PEI)
Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
12 Months to 42 Months
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Nov 14, 2026, 1:26 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Locomotor Learning With Brain Stimulation

NCT06414213
View directory record Official record
Conditions
Motor Learning
Interventions
Motor Imagery (MI), Active tDCS, Sham tDCS
Behavioral · Device
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 99 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 14, 2026, 1:26 AM EST
Completed Phase 1 Interventional

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

NCT03486301
View directory record Official record
Conditions
Tumor, Solid
Interventions
BDB001 (EIK1001), Pembrolizumab
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Sarasota, Florida • Morristown, New Jersey • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 14, 2026, 1:26 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

NCT05095311
View directory record Official record
Conditions
Exercise-induced Arterial Hypoxemia
Interventions
Cetirizine HCl, Placebo
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Nov 14, 2026, 1:26 AM EST
Terminated Not applicable Interventional

How Gas-Filled Intragastric Balloons or Endoscopic Sleeve Gastroplasty Affect Hunger, Hunger Hormones, and Gastric Emptying Compared to Meal Replacements

NCT04306445
View directory record Official record
Conditions
Obesity
Interventions
GF-IGB: Obalon Balloon, Medically Supervised Meal Replacement Program: My New Weigh, Endoscopic sleeve gastroplasty: (ESG)
Device · Dietary Supplement · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 14, 2026, 1:26 AM EST
Completed Phase 1 Interventional

STA-9090 in Patients With Advanced Hepatocellular Cancer

NCT01665937
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
STA-9090
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Nov 14, 2026, 1:26 AM EST
Completed Not applicable Interventional Results available

Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke

NCT03985761
View directory record Official record
Conditions
Stroke
Interventions
Home Telerehabilitation using HoVRS
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
40 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 14, 2026, 1:26 AM EST
Completed Early Phase 1 Interventional Results available

Effects of Rocking on Postoperative Ileus Duration Study

NCT00494806
View directory record Official record
Conditions
Abdominal Cancer
Interventions
Rocking Chair Intervention
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Nov 14, 2026, 1:26 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Single Session Intervention for Building Self-Compassion Habits-RCT

NCT05199779
View directory record Official record
Conditions
Transdiagnostic Psychopathology
Interventions
Single Session Intervention Leveraging an Ultra-Brief Self-Compassion Exercise, Finger-Tapping Active Control
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Nov 14, 2026, 1:26 AM EST
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
CYT387
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Nov 14, 2026, 1:26 AM EST
Terminated Phase 4 Interventional Results available

Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing

NCT03746002
View directory record Official record
Conditions
Fluid Overload, Heart Failure Acute
Interventions
Metolazone 60 minutes prior to furosemide, Metolazone concurrently with furosemide
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Nov 14, 2026, 1:26 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Do Weight Status and the Level of Dietary Restraint Moderate the Relationship Between Package Unit Size and Food Intake?

NCT01384552
View directory record Official record
Conditions
Overweight
Interventions
Package Unit Size - Single Serving, Package Unit Size - Standard
Other
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 35 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Nov 14, 2026, 1:26 AM EST
Completed Phase 4 Interventional

Use of FlexHD as Post Trapeziectomy Spacer

NCT01998594
View directory record Official record
Conditions
Osteoarthrosis of the Carpometacarpal Joint of the Thumb
Interventions
Arthroplasty
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Nov 14, 2026, 1:26 AM EST
Withdrawn Not applicable Interventional

Cardiac Output Monitoring in Burn Patients

NCT02404597
View directory record Official record
Conditions
Burns
Interventions
NICOM (non-invasive cardiac output monitor)
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Nov 14, 2026, 1:26 AM EST
Completed Not applicable Interventional

Mindfulness Intervention to Improve Symptomology Among Cancer Survivors; Focus on Sleep and Stress Improvement

NCT02633748
View directory record Official record
Conditions
Cancer Sequelae
Interventions
Mindfulness-Based Cancer Survivorship
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Nov 14, 2026, 1:26 AM EST
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 14, 2026, 1:26 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Working Memory Training for People Aging With HIV

NCT06699927
View directory record Official record
Conditions
Cognitive Change
Interventions
Span
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
50 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 14, 2026, 1:26 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Understanding Individual Differences in Working Memory Training and Transfer in Older Adults

NCT05396586
View directory record Official record
Conditions
Cognitive Change
Interventions
N-back, Span, Multisensory
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
50 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
2
States / cities
Irvine, California • Riverside, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Nov 14, 2026, 1:26 AM EST
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 14, 2026, 1:26 AM EST
Active, not recruiting Phase 2 Interventional Results available

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

NCT00044304
View directory record Official record
Conditions
Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome
Interventions
Imatinib Mesylate, Ruxolitinib
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 14, 2026, 1:26 AM EST
Terminated Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Celecoxib on Bone Ingrowth

NCT00585156
View directory record Official record
Conditions
Bone Ingrowth, Pain
Interventions
Celecoxib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 95 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Nov 14, 2026, 1:26 AM EST
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions
Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
28 Days and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:26 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

NCT06908096
View directory record Official record
Conditions
EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
Interventions
EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 29 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 14, 2026, 1:26 AM EST